Funding
Blackstone Life Sciences and Boston Scientific in $455M heart pump co-funding deal
Key Facts
Signal Type
Funding
Industry
Biotech
Companies
Boston Scientific, Blackstone Life Sciences, Medtronic
Date
Blackstone Life Sciences has signed a $455 million collaboration with Boston Scientific to co-fund development of the Vitalyst Temporary Percutaneous Transvalvular Circulatory Support System. The device is designed to increase cardiac output and improve blood flow for patients with acute myocardial infarction cardiogenic shock.
This is the first co-funding arrangement between Boston Scientific and Blackstone, though Blackstone previously supported Medtronic's diabetes R&D programs in a similar partnership in 2020.
Boston Scientific's cardiovascular division will lead the program, with Blackstone Life Sciences as the investing partner. The target patient population is critically ill cardiogenic shock patients, where current mechanical circulatory support technologies have limitations in efficacy and safety.
Physicians treating acute heart attacks and related cardiac emergencies are directly affected, as the Vitalyst system aims to improve ease of use and patient outcomes. The program also signals a broader trend of life sciences investors co-funding device development with established medtech companies.
The $455 million capital injection into Boston Scientific's cardiovascular franchise will accelerate the Vitalyst program through development and regulatory milestones. Competitors in the temporary circulatory support space, including those with existing miniature heart pump technologies, will face a better-funded challenger.
Watch for Boston Scientific to announce clinical trial sites and enrollment milestones in coming quarters. The co-funding structure with Blackstone may also set a precedent for similar deals across Boston Scientific's pipeline.
Monitor competitive responses from Medtronic and other circulatory support developers, as well as regulatory progress. Any delay in Vitalyst development would affect the funding outlook and partner expectations.
Source:
Fierce BiotechGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
